In the claims:

Please cancel claims 2 through 16 inclusive.

Please add new claims 17 through 32 as follows:

17. (New) A method for modulating a disease or condition associated with phospholipase D (PLD) initiated polymorphoneutrophil (PMN) inflammation in a subject, comprising

administering to the subject an effective anti-inflammatory amount of a lipoxin analog having the formula



wherein X is R_1, OR_1, or SR_1;

wherein R_1 is

(i) a hydrogen atom;

(ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched;

(iii) a cycloalkyl of 3 to 10 carbon atoms;

(iv) an aralkyl of 7 to 12 carbon atoms;

(v) phenyl;

(vi) substituted phenyl



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, $-CN$, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl;

(vii) a detectable label molecule; or

(viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=O), SO_2 or (CN), provided when Q_1 is CN, then X is absent;
wherein Q_3 and Q_4 are each independently O, S or NH;
wherein one of R_2 and R_3 is a hydrogen atom and the other is

(a) H;

(b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;

(c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;

(d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or

(e) $R_aQ_2R_b$ wherein Q_2 is –O– or –S–; wherein R_a is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;

wherein R_4 is

(a) H;

(b) an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

wherein R_5 is



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, $-CN$, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;

wherein R_6 is

(a) H;

(b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or S, and pharmaceutically acceptable salts thereof, such that a disease or condition associated with PLD initiated polymorphoneutrophil (PMN) inflammation in a subject is modulated.

18. (New) The method of claim 17, wherein said method is performed *in vitro*.

19. (New) The method of claim 17, wherein said method is performed *in vivo*.

20. (New) A method for treating phospholipase D (PLD) initiated polymorphoneutrophil (PMN) inflammation in a subject, comprising

administering to the subject an effective anti-inflammatory amount of a lipoxin analog having the formula



wherein X is R_1, OR_1, or SR_1;

wherein R_1 is

(i) a hydrogen atom;

(ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched;

(iii) a cycloalkyl of 3 to 10 carbon atoms;

(iv) an aralkyl of 7 to 12 carbon atoms;

(v) phenyl;

(vi) substituted phenyl



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, $-CN$, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl;

(vii) a detectable label molecule; or

(viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=O), SO_2 or (CN), provided when Q_1 is CN, then X is absent;
wherein Q_3 and Q_4 are each independently O, S or NH;
wherein one of R_2 and R_3 is a hydrogen atom and the other is

(a) H;

(b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;

(c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;

(d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or

(e) $R_aQ_2R_b$ wherein Q_2 is –O– or –S–; wherein R_a is alkylene of 0 to 6 carbons

atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;

wherein R_4 is

(a) H;

(b) an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

wherein R_5 is



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, $-CN$, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;

wherein R_6 is

(a) H;

(b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or S, and pharmaceutically acceptable salts thereof, such that PLD initiated polymorphoneutrophil (PMN) inflammation is treated in a subject.

21. (New) The method of claim 20, wherein said method is performed *in vitro*.

22. (New) The method of claim 20, wherein said method is performed *in vivo*.

23. (New) A method for modulating a disease or condition associated with phospholipase D (PLD) initiated superoxide generation or degranulation activity in a subject, comprising administering to the subject an effective anti-PLD amount of a lipoxin analog having the formula



wherein X is R_1, OR_1, or SR_1;

wherein R_1 is

(i) a hydrogen atom;

(ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight

chain or branched;

(iii) a cycloalkyl of 3 to 10 carbon atoms;

(iv) an aralkyl of 7 to 12 carbon atoms;

(v) phenyl;

(vi) substituted phenyl



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, $-CN$, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl;

(vii) a detectable label molecule; or

(viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=O), SO_2 or (CN), provided when Q_1 is CN, then X is absent;

wherein Q_3 and Q_4 are each independently O, S or NH;

wherein one of R_2 and R_3 is a hydrogen atom and the other is

(a) H;

(b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;

(c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;

(d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or

branched; or

(e) $R_aQ_2R_b$ wherein Q_2 is –O– or –S–; wherein R_a is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;

wherein R_4 is

(a) H;

(b) an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

wherein R_5 is



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $–NO_2$, –CN, $–C(=O)–R_1$, $–SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;

wherein R_6 is

(a) H;

(b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or S, and pharmaceutically acceptable salts thereof, such that a disease or condition associated with PLD initiated superoxide generation or degranulation activity in a subject is modulated.

24. (New) The method of claim 23, wherein said method is performed *in vitro*.

25. (New) The method of claim 23, wherein said method is performed *in vivo*.

26. (New) A method for treating phospholipase D (PLD) initiated superoxide generation or degranulation in a subject, comprising

administering to the subject an effective anti-PLD amount of a lipoxin analog having the formula



wherein X is R_1, OR_1, or SR_1;

wherein R_1 is

(i) a hydrogen atom;

(ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched;

(iii) a cycloalkyl of 3 to 10 carbon atoms;

(iv) an aralkyl of 7 to 12 carbon atoms;

(v) phenyl;

(vi) substituted phenyl



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, $-CN$, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl;

(vii) a detectable label molecule; or

(viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=O), SO_2 or (CN), provided when Q_1 is CN, then X is absent;
wherein Q_3 and Q_4 are each independently O, S or NH;
wherein one of R_2 and R_3 is a hydrogen atom and the other is

(a) H;

(b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;

(c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;

(d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or

(e) $R_aQ_2R_b$ wherein Q_2 is –O– or –S–; wherein R_a is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_6 is a hydrogen atom;

wherein R_4 is

(a) H;

(b) an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

wherein R_5 is



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, –CN, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or

branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;

wherein R_6 is

(a) H;

(b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or S, and pharmaceutically acceptable salts thereof, such that PLD initiated superoxide generation or granulation is treated in a subject.

27. (New) The method of claim 26, wherein said method is performed *in vitro*.

28. (New) The method of claim 26, wherein said method is performed *in vivo*.

29. (New) A packaged pharmaceutical composition for treating a disease or condition associated with phospholipase D (PLD) initiated activity in a subject, comprising:

a container holding a therapeutically effective amount of at least one lipoxin compound having the formula



wherein X is R_1, OR_1, or SR_1;

wherein R_1 is

(i) a hydrogen atom;

(ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched;

(iii) a cycloalkyl of 3 to 10 carbon atoms;

(iv) an aralkyl of 7 to 12 carbon atoms;

(v) phenyl;

(vi) substituted phenyl



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, $-CN$, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl;

(vii) a detectable label molecule; or

(viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=O), SO_2 or (CN), provided when Q_1 is CN, then X is absent;

wherein Q_3 and Q_4 are each independently O, S or NH;

wherein one of R_2 and R_3 is a hydrogen atom and the other is

(a) H;

(b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;

(c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;

(d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or

(e) $R_aQ_2R_b$ wherein Q_2 is –O– or –S–; wherein R_a is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;

wherein R_4 is

(a) H;

(b) an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

wherein R_5 is



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $–NO_2$, –CN, $–C(=O)–R_1$, $–SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;

wherein R_6 is

(a) H;

(b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or S, and pharmaceutically acceptable salts thereof; and

instructions for using said lipoxin compound for treating a disease or condition associated with PLD initiated activity in the subject.

30. (New) A packaged pharmaceutical composition for treating phospholipase D initiated activity in a subject, comprising:

a container holding a therapeutically effective amount of at least one lipoxin compound having the formula



wherein X is R_1, OR_1, or SR_1;

wherein R_1 is

(i) a hydrogen atom;

(ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched;

(iii) a cycloalkyl of 3 to 10 carbon atoms;

(iv) an aralkyl of 7 to 12 carbon atoms;

(v) phenyl;

(vi) substituted phenyl



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, $-CN$, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl;

(vii) a detectable label molecule; or

(viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=O), SO_2 or (CN), provided when Q_1 is CN, then X is absent;
wherein Q_3 and Q_4 are each independently O, S or NH;
wherein one of R_2 and R_3 is a hydrogen atom and the other is

(a) H;

(b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;

(c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;

(d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or

(e) $R_aQ_2R_b$ wherein Q_2 is –O– or –S–; wherein R_a is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;

wherein R_4 is

(a) H;

(b) an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

wherein R_5 is



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $–NO_2$, –CN, $–C(=O)–R_1$, $–SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;

wherein R_6 is

(a) H;

(b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or S, and pharmaceutically acceptable salts thereof; and

instructions for using said lipoxin compound for treating PLD initiated activity in the subject.

31. (New) A packaged pharmaceutical composition for treating a disease or condition associated with phospholipase D (PLD) initiated superoxide generation or degranulation activity in a subject, comprising:

a container holding a therapeutically effective amount of at least one lipoxin compound having the formula



wherein X is R_1, OR_1, or SR_1;

wherein R_1 is

(i) a hydrogen atom;

(ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched;

(iii) a cycloalkyl of 3 to 10 carbon atoms;

(iv) an aralkyl of 7 to 12 carbon atoms;

(v) phenyl;

(vi) substituted phenyl



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, $-CN$, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl;

(vii) a detectable label molecule; or

(viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=O), SO_2 or (CN), provided when Q_1 is CN, then X is absent;

wherein Q_3 and Q_4 are each independently O, S or NH;

wherein one of R_2 and R_3 is a hydrogen atom and the other is

(a) H;

(b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;

(c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;

(d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or

(e) $R_aQ_2R_b$ wherein Q_2 is –O– or –S–; wherein R_a is alkylene of 0 to 6 carbons

atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when R_b is 0, then R_b is a hydrogen atom;

wherein R_4 is

(a) H;

(b) an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

wherein R_5 is



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, $-CN$, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;

wherein R_6 is

(a) H;

(b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or S, and pharmaceutically acceptable salts thereof; and

instructions for using said lipoxin compound for treating a disease or condition associated with PLD initiated superoxide generation or degranulation activity in the subject.

32. (New) A packaged pharmaceutical composition for treating phospholipase D (PLD) initiated superoxide generation or degranulation activity in a subject, comprising:

a container holding a therapeutically effective amount of at least one lipoxin compound having the formula



wherein X is R_1, OR_1, or SR_1;

wherein R_1 is

(i) a hydrogen atom;

(ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched;

(iii) a cycloalkyl of 3 to 10 carbon atoms;

(iv) an aralkyl of 7 to 12 carbon atoms;

(v) phenyl;

(vi) substituted phenyl



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, $-CN$, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl;

(vii) a detectable label molecule; or

(viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein Q_1 is (C=O), SO_2 or (CN), provided when Q_1 is CN, then X is absent;
wherein Q_3 and Q_4 are each independently O, S or NH;
wherein one of R_2 and R_3 is a hydrogen atom and the other is

(a) H;

(b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;

(c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;

(d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or

(e) $R_aQ_2R_b$ wherein Q_2 is –O– or –S–; wherein R_a is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein R_b is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched,

provided when R_b is 0, then R_b is a hydrogen atom;

wherein R_4 is

(a) H;

(b) an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

wherein R_5 is



wherein Z_i, Z_{ii}, Z_{iii}, Z_{iv} and Z_v are each independently selected from $-NO_2$, $-CN$, $-C(=O)-R_1$, $-SO_3H$, a hydrogen atom, halogen, methyl, $-OR_x$, wherein R_x is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein Y_1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH_aZ_b where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;

wherein R_6 is

(a) H;

(b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein T is O or S, and pharmaceutically acceptable salts thereof; and

instructions for using said lipoxin compound for treating PLD initiated superoxide generation or degranulation activity in the subject.

REMARKS

Claims 1 and 17 through 32 are pending.

The specification has been amended to correct for an obvious typographical errors on pages 11, 14, 17 and 19 and to more clearly define the invention.

Attached hereto is a marked up version of the changes made to the claims by the current amendment. The attached pages are captioned "Version with Markings to Show Changes Made."